Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn

J Pediatr. 1999 Mar;134(3):349-51. doi: 10.1016/s0022-3476(99)70462-2.


Subcutaneous fat necrosis of the newborn (SCFN) is characterized by indurated violet skin nodules and, occasionally, life-threatening hypercalcemia. Current treatments of patients with SCFN-related hypercalcemia are often only partially successful and may be associated with prolonged hypercalcemia. We now report the use of etidronate, a bisphosphonate, to control hypercalcemia in an infant with SCFN.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Etidronic Acid / therapeutic use*
  • Fat Necrosis / diagnosis
  • Fat Necrosis / drug therapy*
  • Fat Necrosis / metabolism
  • Humans
  • Hypercalcemia / diagnosis
  • Hypercalcemia / drug therapy*
  • Hypercalcemia / metabolism
  • Infant
  • Male
  • Remission Induction


  • Etidronic Acid